Skip to content

Transcatheter arterial micro-embolization (TAME) using imipenem/cilastatin sodium for chronic musculoskeletal pain chronic musculoskeletal pain resistant to conservative treatment

Transcatheter arterial micro-embolization (TAME) using imipenem/cilastatin sodium for chronic musculoskeletal pain chronic musculoskeletal pain resistant to conservative treatment - Clinical efficacy of TAME for chronic musculoskeletal pain

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031797
Enrollment
50
Registered
2018-04-01
Start date
2018-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lateral humeral epicondylitis, medial humeral epicondylitis, shoulder periarthritis, intractable pain after artificial joint surgery, knee osteoarthritis, hip osteoarthritis

Interventions

Sponsors

Wakayama medical university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Previous conservative therapies applied for at least 3 months and persistent moderate-to-severe hip pain (NRS>=5). 2) Patients with maintain major organ (bone marrow, heart, liver, lung, kidney) function. Hb: more than 10.0g/dL WBC: more than 3,000/mm3, less than 12,000/mm3 Plt: more than 70,000/mm3 Cr: less than 1.5mg/dL 3) 20 years of age or older and less than 80 years of age, gender is unquestioned 4) Patients with possibility of going to hospital and follow up for 6 months. 5) Provided written informed consent to undergo the procedure.

Exclusion criteria

Exclusion criteria: 1)Surgical candidate 2)Patients with major depression 3)Patients with uncontrollable diabetic mellitus 4)Patients without possibility of going to hospital and follow up for 6 months. 5)Patient who was decided not to be appropriate for this trial by physician 6)Patients with a history of hypersensitivity or shock to antibiotics of imipenem . cilastatin, carbapenem, penicillin or cephem 7)Patients who are receiving sodium valproate 8)Patients with a history of severe thrombotic symptoms such as myocardial infarction and cerebral infarction 9)Patients diagnosed as anti-phospholipid antibody syndrome 10)Patients performing antiplatelet drugs or anticoagulation therapy 11)Patients diagnosed as collagen diseases such as rheumatoid arthritis and polymyalgia rheumatic 12)Pregnant patient

Design outcomes

Primary

MeasureTime frame
Clinical efficacy 1) Numerical Rating Scale (NRS) in 6 months after the procedure 2) Quality of life (QOL) in 6 months after the procedure

Secondary

MeasureTime frame
Incidence of adverse events

Countries

Japan

Contacts

Public ContactAkira Ikoma

Wakayama medical university Department of Radiology

w-akira@wakayama-med.ac.jp073-447-2300

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026